Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMKZRBP)

• Drug Name: LITOXETINE Drug Info
• Synonyms: Litoxetine; 86811-09-8; 4-(2-Naphthylmethoxy)piperidine; UNII-9980ST005G; CHEMBL471036; 9980ST005G; Litoxetinum; Litoxetina; Litoxetine [INN]; Litoxetinum [INN-Latin]; Litoxetina [INN-Spanish]; AC1L23OW; SCHEMBL119884; ZINC3647; CTK3E8854; DTXSID30235828; BDBM50278564; 4-(naphthalen-2-ylmethoxy)piperidine

Indication

Disease Entry	ICD 11	Status	REF
Mood disorder	6A60-6E23	Phase 3	[1]

• Cross-matching ID:
  PubChem CID: 65650
  CAS Number: CAS 86811-09-8
  TTD Drug ID: DMKZRBP
  VARIDT Drug ID: DR00778

Molecule-Related Drug Atlas

Drug(s) Targeting Serotonin transporter (SERT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[3]
Amitriptyline	DMK7F9S	Depression	6A70-6A7Z	Approved	[4]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[5]
Vortioxetine	DM6F1PU	Major depressive disorder	6A70.3	Approved	[6]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[7]
Cocaine	DMSOX7I	Anaesthesia	9A78.6	Approved	[8]
Bupropion	DM5PCS7	Depression	6A70-6A7Z	Approved	[9]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[5]
Nortriptyline	DM4KDYJ	Depression	6A70-6A7Z	Approved	[5]
Trazodone	DMK1GBJ	Depression	6A70-6A7Z	Approved	[5]

Drug(s) Targeting 5-HT 3 receptor (5HT3R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ondansetron	DMOTQ1I	Chemotherapy-induced nausea	MD90	Approved	[10]
Granisetron	DMIUW25	Malignant glioma	2A00.0	Approved	[11]
Ramosetron	DMH7GN8	Diarrhea-predominant irritable bowel syndrome	DD91.01	Approved	[12]
Y-25130	DMDPM7R	Nausea and vomiting	MD90	Approved	[13]
Renzapride	DM7HQNX	Irritable bowel syndrome	DD91.0	Phase 3	[14]
Zatosetron maleate	DMWDEFC	Anxiety disorder	6B00-6B0Z	Phase 3	[15]
Pancopride	DMIRYU9	Nausea	MD90	Phase 3	[16]
Lerisetron	DMOTCIU	Nausea	MD90	Phase 3	[17]
Lintopride	DMSHGWN	Nausea	MD90	Phase 2	[18]
DDP-225	DM9REBL	Irritable bowel syndrome	DD91.0	Phase 2	[19]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
5-HT 3 receptor (5HT3R)	TTNXLKE	NOUNIPROTAC	Modulator	[2]
Serotonin transporter (SERT)	TT3ROYC	SC6A4_HUMAN	Modulator	[2]

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001264)
• [2] Litoxetine: a selective 5-HT uptake inhibitor with concomitant 5-HT3 receptor antagonist and antiemetic properties. Eur J Pharmacol. 1993 Mar 2;232(2-3):139-45.
• [3] Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology (Berl). 2009 Sep;206(1):97-107.
• [4] Treatment of comorbid pain with serotonin norepinephrine reuptake inhibitors. CNS Spectr. 2008 Jul;13(7 Suppl 11):22-6.
• [5] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [6] Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
• [7] Psychopharmacological treatment of dermatological patients--when simply talking does not help. J Dtsch Dermatol Ges. 2007 Dec;5(12):1101-6.
• [8] Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav. 2009 Jul;93(1):75-81.
• [9] Clinically relevant drug interactions with new generation antidepressants and antipsychotics. Ther Umsch. 2009 Jun;66(6):485-92.
• [10] Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron: a randomized, placebo-controlled, double-blind cross-over trial. Eur J Gastroenterol Hepatol. 1998 Oct;10(10):865-70.
• [11] New approaches to chemotherapy-induced nausea and vomiting: from neuropharmacology to clinical investigations. Cancer J. 2006 Sep-Oct;12(5):341-7.
• [12] Inhibitory effect of YM060 on 5-HT3 receptor-mediated depolarization in colonic myenteric neurons of the guinea pig. Eur J Pharmacol. 1995 Sep 5;283(1-3):107-12.
• [13] The antiemetic profile of Y-25130, a new selective 5-HT3 receptor antagonist. Eur J Pharmacol. 1991 Apr 24;196(3):299-305.
• [14] Pharmacology and metabolism of renzapride : a novel therapeutic agent for the potential treatment of irritable bowel syndrome. Drugs R D. 2008;9(1):37-63.
• [15] Pilot study of zatosetron (LY277359) maleate, a 5-hydroxytryptamine-3 antagonist, in the treatment of anxiety. J Clin Psychopharmacol. 1999 Apr;19(2):125-31.
• [16] Pancopride, a potent and long-acting 5-HT3 receptor antagonist, is orally effective against anticancer drug-evoked emesis. Eur J Pharmacol. 1992 Nov 10;222(2-3):257-64.
• [17] Emerging drugs for chemotherapy-induced emesis. Expert Opin Emerg Drugs. 2006 Mar;11(1):137-51.
• [18] The effects of lintopride, a 5HT-4 antagonist, on oesophageal motility. Aliment Pharmacol Ther. 1995 Oct;9(5):563-9.
• [19] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.